1.81
-0.01(-0.55%)
Currency In USD
Address
855 North Wolfe Street
Baltimore, MD 21205
United States of America
Phone
856 848 8698
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
January 23, 2014
| Name | Title | Pay | Year Born |
| Mr. Ian Rhodes CPA | Interim Chief Financial Officer | 162,000 | 1973 |
| Dr. Mitchell Glass M.D. | President, Chief Medical Officer & Director | 0 | 1952 |
| Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development | 0 | N/A |
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.